Informations:
Erreur:
ID
34429
Description
LDK378 in Adult Chinese Patients With ALK-rearranged (ALK-positive) Advanced Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib; ODM derived from: https://clinicaltrials.gov/show/NCT02040870
Lien
https://clinicaltrials.gov/show/NCT02040870
Mots-clés
Versions (1)
- 17/01/2019 17/01/2019 -
Détendeur de droits
see on clinicaltrials.gov
Téléchargé le
17 janvier 2019
DOI
Pour une demande vous connecter.
Licence
Creative Commons BY 4.0
Modèle Commentaires :
Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.
Groupe Item commentaires pour :
Item commentaires pour :
Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.
Eligibility Non-Small Cell Lung Cancer NCT02040870
Eligibility Non-Small Cell Lung Cancer NCT02040870
- StudyEvent: Eligibility
Similar models
Eligibility Non-Small Cell Lung Cancer NCT02040870
- StudyEvent: Eligibility
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
ID.1
Item
histologically or cytologically confirmed diagnosis of nsclc that carries an alk rearrangement defined as positive using the fda approved vysis alk break apart fish probe kit (abbott molecular inc.) test and scoring algorithm (including positivity criteria) or positive as assessed by the cfda approved immunohistochemistry (ihc) test (ventana medical systems, inc)
boolean
ID.2
Item
age 18 years or older at the time of informed consent.
boolean
ID.3
Item
patients must have stage iiib or iv nsclc at the time of study entry and have had progressive disease during or after crizotinib treatment whether or not previously treated with cytotoxic chemotherapy. if treated with chemotherapy, maximum 2 lines are allowed.
boolean
ID.4
Item
patients with known hypersensitivity to any of the excipients of ldk378
boolean
ID.5
Item
patients with symptomatic central nervous system (cns) metastases who are neurologically unstable or have required increasing doses of steroids within the 2 weeks prior to study entry to manage cns symptoms
boolean
ID.6
Item
history of carcinomatous meningitis
boolean
ID.7
Item
presence or history of a malignant disease other than nsclc that has been diagnosed and/or required therapy within the past 3 years.
boolean
ID.8
Item
clinically significant, uncontrolled heart disease.
boolean